<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05099315</url>
  </required_header>
  <id_info>
    <org_study_id>Microbiome and AD</org_study_id>
    <nct_id>NCT05099315</nct_id>
  </id_info>
  <brief_title>Microbiome in Atopic Dermatitis Under Systemic Therapy</brief_title>
  <acronym>BIO-AD</acronym>
  <official_title>Identification of Skin-associated Microbiota in Atopic Dermatitis Patients Undergoing Systemic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The skin microbiome plays a role in the pathogenesis of atopic dermatitis. However, it is&#xD;
      unclear whether the range of microbiota on the skin is the cause or consequence of atopic&#xD;
      skin inflammation.&#xD;
&#xD;
      The influence of new systemic therapies for the treatment of moderate to severe atopic&#xD;
      dermatitis (such as biologics or Janus kinase inhibitors) on the skin microbiome is largely&#xD;
      unknown.&#xD;
&#xD;
      The main aim of this scientific exploratory study is to investigate whether and how the skin&#xD;
      microbiome changes in patients with moderate to severe atopic dermatitis during systemic&#xD;
      therapy. This not only allows new hypotheses to be generated on the pathogenesis of atopic&#xD;
      dermatitis, but also new objective scales for the severity of atopic dermatitis can be&#xD;
      developed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A better understanding of the pathology of atopic dermatitis could lead to the development of&#xD;
      new therapeutic strategies for this disease and contribute to better and more targeted&#xD;
      disease management - an advantage for all patients with atopic dermatitis.&#xD;
&#xD;
      The routine examinations are carried out every quarter with routine visits over two years.&#xD;
      The dates before, 6, 12, and 24 months after the initiation of systemic therapy are relevant&#xD;
      for this study. Deviations from normal practice are not intended.&#xD;
&#xD;
      Patients in whom a new initiation of systemic therapy is planned will be invited for a&#xD;
      follow-up 6 weeks after initiation and quarterly follow-up visits.&#xD;
&#xD;
      Blood samples must be obtained for the examination. The blood is taken to determine the&#xD;
      systemic level of inflammatory mediators (serological biomarkers, PBMCs) and for genetic&#xD;
      examinations (e.g. filaggrin gene mutation - FLG) as well as mRNA / lncRNA profile. The skin&#xD;
      physiological examinations are not invasive or pain-related procedures. Microbiome sampling&#xD;
      will be conducted by a skin swab of the inter-scapular region.&#xD;
&#xD;
      The blood / skin samples taken as part of this scientific study are pseudonymized in the&#xD;
      research laboratories. The samples are stored in the laboratories for a period of 5 years&#xD;
      after the end of the study and then destroyed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Comparison of the microbial composition</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of the microbial composition of the skin before, 6 and 12 months after the initiation of systemic therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of microbial composition of the skin with serological biomarkers</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of microbial composition of the skin with serological biomarkers (z.B.TARC, TSLP, CCL27).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbial composition and skin barrier function</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of the microbial composition of the skin with the skin physiology (including transepidermal water loss, sebumetry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of main microbial representants of skin microbiome</measure>
    <time_frame>1 year</time_frame>
    <description>Correlation of the S. aureus to the P. acnes ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of microbiome and severity of atopic dermatitis EASI</measure>
    <time_frame>2 years</time_frame>
    <description>Correlation of the microbiome with the Eczema Area and Severity Index (EASI). EASI ranges from 0-72, increasing severity with increasing score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of microbiome and severity of atopic dermatitis SCORAD</measure>
    <time_frame>2 years</time_frame>
    <description>Correlation of the microbiome with Scoring of Atopic Dermatitis (SCORAD). SCORAD ranges from 0-103, increasing severity with increasing score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of the skin microbiome with the mRNA EASI</measure>
    <time_frame>2 years</time_frame>
    <description>Correlation of the main representants of skin microbiota and the Eczema Area and Severity Index (EASI). EASI ranges from 0-72, increasing severity with increasing score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of the skin microbiome with the mRNA SCORAD</measure>
    <time_frame>2 years</time_frame>
    <description>Correlation of the main representants of skin microbiota and Scoring of Atopic Dermatitis (SCORAD). SCORAD ranges from 0-103, increasing severity with increasing score.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Dupilumab treated Patients (observational)</arm_group_label>
    <description>Patients with atopic dermatitis with indication for dupilumab treatment will be observed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclosporine treated Patients (observational)</arm_group_label>
    <description>Patients with atopic dermatitis with indication for cyclosporine treatment will be observed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baricitinib treated Patients (observational)</arm_group_label>
    <description>Patients with atopic dermatitis with indication for baricitinib treatment will be observed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>not applicable, observational study</intervention_name>
    <description>Patients undergoing systemic therapy according to international accepted guidelines for the therapy of atopic dermatitis, observational study</description>
    <arm_group_label>Baricitinib treated Patients (observational)</arm_group_label>
    <arm_group_label>Cyclosporine treated Patients (observational)</arm_group_label>
    <arm_group_label>Dupilumab treated Patients (observational)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      1. Serum,&#xD;
&#xD;
        2. Peripheral blood mononuclear cells&#xD;
&#xD;
        3. Skin swab for microbiome analysis&#xD;
&#xD;
        4. Genetic examination of the filaggringen mutation status&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients with moderate to severe atopic dermatitis presenting in the clinic of&#xD;
        Dermatology, Charité - Universitätsmedizin Berlin, Germany.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with moderate to severe atopic dermatitis&#xD;
&#xD;
          -  Indication for systemic therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under 18 years of age upon introducing systemic therapy&#xD;
&#xD;
          -  Pregnant and lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Margitta Worm, Prof</last_name>
    <phone>+49 30 450 518105</phone>
    <email>margitta.worm@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sabine Dölle-Bierke, PhD</last_name>
    <phone>+49 30 450 518367</phone>
    <email>sabine.doelle@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dpt of Dermatology and Allergology, Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Dölle-Bierke, PhD</last_name>
      <phone>+49 30 450 518367</phone>
      <email>sabine.doelle@charite.de</email>
    </contact>
    <investigator>
      <last_name>Wojciech Francuzik, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margitta Worm, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Margitta Worm</investigator_full_name>
    <investigator_title>Prof. Dr. med. Margitta Worm</investigator_title>
  </responsible_party>
  <keyword>dupilumab</keyword>
  <keyword>cyclosporine</keyword>
  <keyword>skin microbiome</keyword>
  <keyword>baricitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

